Article

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users

Department of Family and Preventive Medicine, University of California, San Diego, San Diego, California, United States
Drug and Alcohol Review (Impact Factor: 1.55). 10/2006; 25(5):451-4. DOI: 10.1080/09595230600883313
Source: PubMed

ABSTRACT Improving access to antiretroviral therapy among injection drug users remains an urgent public health concern. We examined the time to antiretroviral therapy (ART) use among antiretroviral naive HIV-infected injection drug users who were unaware of their HIV status to examine the impact of receipt of HIV test results on uptake of ART. Time to ART use was examined using Kaplan - Meier methods, and factors associated with the time to ART were evaluated using Cox proportional hazards regression. Between May 1996 and May 2003, 312 HIV-infected individuals were enrolled into the Barriers to Antiretroviral Therapy (BART) cohort, among whom 105 (33.7%) reported not knowing their HIV status at baseline. At 24 months post-baseline, those participants who returned for test results within 8 months initiated ART at a significantly elevated rate [adjusted relative hazard = 1.87 (95% CI: 1.05 - 3.33)]. These findings demonstrate the potential to improve uptake of ART among injection drug users through targeted HIV testing and counselling initiatives that encourage the receipt of HIV test results, and suggest that strategies to improve awareness of HIV infection may improve access to antiretroviral therapy.

1 Follower
 · 
94 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Achtergrond en doel: Drugsgebruikers (DG) zijn de grootste risicopopulatie voor besmetting met HCV. De Gemeente Gezondheidsdienst (GGD) van Amsterdam heeft het Drug Users Treatment for Chronic Hepatitis C (Dutch-C) project opgezet om DG te screenen en optimaal te kunnen behandelen. De doelen van deze studie waren (1) het begrijpen van de huidige en vroegere redenen waarom een deel van de DG behandeling geweigerd hebben en (2) redenen waarom DG uiteindelijk hebben toegestemd in behandeling. Deze informatie kan gebruikt worden voor verbetering van de HCV behandelingsmogelijkheden en de versterking van campagnes en overtuigende communicatie voor toekomstige inclusie in HCV behandeling bij DG. Methoden: Binnen dit onderzoek werd de kwalitatieve Grounded Theory (GT) methode gevolgd. Selectie van participanten vond plaats door middel van een doelgerichte steekproef uit de Dutch-C populatie. Dataverzameling vond plaats door middel van semigestructureerde interviews. De interviews werden opgenomen op band, getranscribeerd en geanalyseerd door middel van open codering. Interpretatie van data geschiedde volgens het Health Belief model. Resultaten: In totaal participeerden 22 DG in dit onderzoek. Gerapporteerde barrières waren verkeerde aannames over de ziekte, angst voor bijwerkingen, twijfel over de werkzaamheid van therapie, geen geloof in medische interventies, frustratie over communicatie tussen hulpverleners, kennistekort, ziekteontkenning en afwijzing van gezondheidszorginstantie. Motieven voor DG die behandeling gestart zijn waren het vermijden van negatieve lichamelijke consequenties gerelateerd aan HCV, zich beter willen voelen, vertrouwen in de organisatie of hulpverleners, het zien van de behandeling als kans en de invloed van andere mensen die behandeling volgen. Conclusie: Lage waargenomen bedreiging van de ziekte gebaseerd op verkeerde aannames over ziekte en behandeling, kennistekort en ziekteontkenning vormt veelal de basis voor weigeren van de behandeling. De kosten van de behandeling in de vorm van bijwerkingen worden als proportioneel hoog ervaren. Waargenomen vatbaarheid en ernst van de ziekte moeten verhoogd worden en kosten van de behandeling moeten verlaagd worden door middel van adequate voorlichting. Voor DG die behandeling in het verleden geweigerd hebben blijkt juist kennis over de gevolgen, ofwel hoge ervaren ernst en vatbaarheid voor de ziekte, een motief voor behandeling te zijn.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many cities throughout the globe are experiencing ongoing infectious disease and overdose epidemics among injection drug users (IDUs). In particular, HIV has become endemic among IDUs in many settings. In an effort to reduce this and related public health concerns, medically supervised safer injecting facilities (SIFs), where IDUs can inject pre-obtained illicit drugs under the supervision of medical staff, have been established in several countries. The following review assesses the role that SIFs can play in reducing the harms associated with HIV infection among IDUs and points to ways in which SIFs can be further developed to better respond to the challenges associated with HIV/AIDS among this population.
    Current HIV/AIDS Reports 01/2008; 4(4):158-64. DOI:10.1007/s11904-007-0023-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Globally, injection drug use continues to account for a substantial proportion of HIV infections. There have not, however, been any evidence-based reviews of the barriers and facilitators of HIV treatment among injection drug users. For this review, published studies were extracted from nine academic databases, with no language or date specified in the search criteria. Existing evidence demonstrates that, although injection drug users often have worse outcomes from HIV treatment than non-injection drug users, major antiretroviral-associated survival gains still have been observed among this population. Inferior outcomes are explained by a range of barriers to antiretroviral access and adherence, which often stem from the negative influences of illicit drug policies, as well as issues within medical systems, including lack of physician education about substance abuse. Evidence demonstrates that several under-utilized interventions and novel antiretroviral delivery modalities have helped to greatly address these barriers in several settings, and there is sufficient evidence to support immediate scale-up of these programmes. These interventions include coupling antiretroviral therapy with opioid substitution therapies as well as directly administered antiretroviral therapy programmes. Of particular interest for future evaluation is the coupling of HIV treatment programmes within comprehensive services, which also provide low-threshold (harm reduction) HIV prevention programmes. Scale-up of evidence-based HIV treatment and prevention to injection drug users, however, will require increasing political will among both national policy-makers and international public health agencies.
    AIDS (London, England) 08/2008; 22(11):1247-56. DOI:10.1097/QAD.0b013e3282fbd1ed · 6.56 Impact Factor
Show more